Drugs / TAK-058
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02614586 | Dec 2015 → Apr 2016 | schizophrenia | Takeda | Terminated | No outcome recorded |
| Phase 1 | NCT02389881 | Feb → Dec 2015 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT02153099 | Jun → Nov 2014 | — | Takeda | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-11-16 | Cerevance Beta, Inc. | Results Cerevance’s CVN058 Achieves Primary Endpoint in Phase 1b Schizophrenia Cognition Study cerevance.com ↗
Cerevance, a private drug discovery and development company focused on brain diseases, today announced positive results from a Phase 1b clinical trial evaluating the company’s oral compound, CVN058, in a biomarker study evaluating its potential as a treatment for cognitive impairment associated with schizophrenia (CIAS). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-11-16 | Cerevance Beta, Inc. | Cerevance’s CVN058 Achieves Primary Endpoint in Phase 1b Schizophrenia Cognition Study cerevance.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-058 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02389881 ↗ |
| Known as | ENV8058 | “The drug being tested in this study is called ENV8058 (also known as TAK-058).” NCT02153099 ↗ |
| Route | Oral | “when administered as a single oral dose in healthy adults” NCT02153099 ↗ |